Nicolas Wein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11700880/publications.pdf

Version: 2024-02-01

| | | 567281 | 610901 |
|----------|----------------|--------------|----------------|
| 25 | 745 | 15 | 24 |
| papers | citations | h-index | g-index |
| | | | |
| | | | |
| | | | |
| 28 | 28 | 28 | 898 |
| all docs | docs citations | times ranked | citing authors |
| | | | |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy. Human Mutation, 2022, 43, 511-528. | 2.5 | 16 |
| 2 | Designed U7 snRNAs inhibitÂDUX4Âexpression and improve FSHD-associated outcomes inÂDUX4Âoverexpressing cells and FSHD patient myotubes. Molecular Therapy - Nucleic Acids, 2021, 23, 476-486. | 5.1 | 17 |
| 3 | Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders. Journal of Visualized Experiments, 2021, , . | 0.3 | O |
| 4 | Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping. Molecular Therapy - Methods and Clinical Development, 2021, 21, 325-340. | 4.1 | 21 |
| 5 | Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting <i>DMD</i> Exon 2 Duplications. Human Gene Therapy, 2021, 32, 1346-1359. | 2.7 | 8 |
| 6 | U7 snRNA, a Small RNA with a Big Impact in Gene Therapy. Human Gene Therapy, 2021, 32, 1317-1329. | 2.7 | 5 |
| 7 | Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce <i>DMD</i> Exon 2 Skipping. Human Gene Therapy, 2021, 32, 882-894. | 2.7 | 29 |
| 8 | X-linked muscular dystrophy in a Labrador Retriever strain: phenotypic and molecular characterisation. Skeletal Muscle, 2020, 10, 23. | 4.2 | 12 |
| 9 | Alternate Translational Initiation of Dystrophin: A Novel Therapeutic Approach. , 2019, , 371-382. | | 0 |
| 10 | Personalized gene and cell therapy for Duchenne Muscular Dystrophy. Neuromuscular Disorders, 2018, 28, 803-824. | 0.6 | 45 |
| 11 | Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach. Journal of Neuromuscular Diseases, 2017, 4, 199-207. | 2.6 | 27 |
| 12 | Dp412e: a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells. Skeletal Muscle, 2015, 5, 40. | 4.2 | 28 |
| 13 | Exon 32 Skipping of Dysferlin Rescues Membrane Repair in Patients' Cells. Journal of Neuromuscular Diseases, 2015, 2, 281-290. | 2.6 | 29 |
| 14 | The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development. Neuromuscular Disorders, 2015, 25, 827-834. | 0.6 | 27 |
| 15 | Clinical phenotypes as predictors of the outcome of skipping around <scp><i>DMD</i></scp> exon 45. Annals of Neurology, 2015, 77, 668-674. | 5.3 | 38 |
| 16 | Genetics and Emerging Treatments for Duchenne and Becker Muscular Dystrophy. Pediatric Clinics of North America, 2015, 62, 723-742. | 1.8 | 71 |
| 17 | Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice. Nature Medicine, 2014, 20, 992-1000. | 30.7 | 113 |
| 18 | Becker muscular dystrophy with widespread muscle hypertrophy and a non-sense mutation of exon 2. Neuromuscular Disorders, 2013, 23, 192. | 0.6 | 1 |

| # | Article | IF | CITATION |
|----|---|------|----------|
| 19 | Fullâ€length dysferlin expression driven by engineered human dystrophic blood derived <scp>CD</scp> 133+ stem cells. FEBS Journal, 2013, 280, 6045-6060. | 4.7 | 12 |
| 20 | UMD-DYSF, a novel locus specific database for the compilation and interactive analysis of mutations in the dysferlin gene. Human Mutation, 2012, 33, E2317-E2331. | 2.5 | 35 |
| 21 | Translational Research and Therapeutic Perspectives in Dysferlinopathies. Molecular Medicine, 2011, 17, 875-882. | 4.4 | 36 |
| 22 | Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Human Mutation, 2010, 31, 136-142. | 2.5 | 80 |
| 23 | Therapeutic exon  switching' for dysferlinopathies?. European Journal of Human Genetics, 2010, 18, 969-970. | 2.8 | 7 |
| 24 | A Naturally Occurring Human Minidysferlin Protein Repairs Sarcolemmal Lesions in a Mouse Model of Dysferlinopathy. Science Translational Medicine, 2010, 2, 50ra69. | 12.4 | 69 |
| 25 | Identification of Different Genomic Deletions and One Duplication in the Dysferlin Gene Using Multiplex Ligation-Dependent Probe Amplification and Genomic Quantitative PCR. Genetic Testing and Molecular Biomarkers, 2009, 13, 439-442. | 0.7 | 18 |